Amylin, Lilly call it quits with exenatide to resolve legal dispute
This article was originally published in Scrip
Executive Summary
Longtime partners Amylin Pharmaceuticals and Lilly decided the best way to resolve their legal dispute was to call it quits for their collaboration involving the diabetes drug exenatide, a synthetic compound derived from the saliva of the Gila monster lizard.